PT2016102E - Recetores de célula t quimérica e materiais relacionados e métodos de uso - Google Patents

Recetores de célula t quimérica e materiais relacionados e métodos de uso Download PDF

Info

Publication number
PT2016102E
PT2016102E PT07797329T PT07797329T PT2016102E PT 2016102 E PT2016102 E PT 2016102E PT 07797329 T PT07797329 T PT 07797329T PT 07797329 T PT07797329 T PT 07797329T PT 2016102 E PT2016102 E PT 2016102E
Authority
PT
Portugal
Prior art keywords
methods
tcr
chimeric
host
tcrs
Prior art date
Application number
PT07797329T
Other languages
English (en)
Inventor
Steven A Rosenberg
Richard A Morgan
Cyrille J Cohen
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38668547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2016102(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of PT2016102E publication Critical patent/PT2016102E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT07797329T 2006-05-03 2007-05-03 Recetores de célula t quimérica e materiais relacionados e métodos de uso PT2016102E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79685306P 2006-05-03 2006-05-03

Publications (1)

Publication Number Publication Date
PT2016102E true PT2016102E (pt) 2012-05-15

Family

ID=38668547

Family Applications (1)

Application Number Title Priority Date Filing Date
PT07797329T PT2016102E (pt) 2006-05-03 2007-05-03 Recetores de célula t quimérica e materiais relacionados e métodos de uso

Country Status (9)

Country Link
US (2) US20090304657A1 (pt)
EP (1) EP2016102B1 (pt)
AT (1) ATE550356T1 (pt)
AU (1) AU2007248019B2 (pt)
CA (1) CA2651174A1 (pt)
DK (1) DK2016102T3 (pt)
ES (1) ES2382777T3 (pt)
PT (1) PT2016102E (pt)
WO (1) WO2007131092A2 (pt)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
DE102006041455B4 (de) * 2006-09-04 2011-07-28 Johannes-Gutenberg-Universität Mainz, 55122 Verfahren zur Herstellung einer einen stabilisierten funktionellen humanen Einzelketten-Antigen-erkennenden-TCR (scTCR) exprimierenden Zelllinie, damit hergestellt Zelllinie, stabilisierter TAA-spezifischer scTCR, deren Verwendungen und diese enthaltende pharmazeutische Zusammmensetzungen
WO2008039818A2 (en) * 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
EP2318434A1 (en) * 2008-07-31 2011-05-11 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Her2/neu specific t cell receptors
EP2186825A1 (en) * 2008-11-13 2010-05-19 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Human-derived T cell receptors
CA2743669C (en) 2008-11-24 2018-10-16 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) High affinity t cell receptor and use thereof
WO2010075417A1 (en) * 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
WO2010088160A1 (en) * 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
EP2424887B1 (en) 2009-04-30 2015-09-30 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inducible interleukin-12
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
GB0917094D0 (en) * 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
CA2811788C (en) * 2010-09-21 2020-12-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-ssx-2 t cell receptors and related materials and methods of use
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
KR102148387B1 (ko) * 2011-10-28 2020-08-26 리제너론 파아마슈티컬스, 인크. 유전자 변형된 ｔ 세포 수용체 마우스
EP2847223B1 (en) 2012-05-07 2019-03-27 Trustees of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
WO2013177247A1 (en) 2012-05-22 2013-11-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Murine anti-ny-eso-1 t cell receptors
SG10201700442QA (en) 2012-07-27 2017-03-30 Univ Illinois Engineering t-cell receptors
WO2014039044A1 (en) 2012-09-06 2014-03-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t memory stem cell populations
TR201905447T4 (tr) 2012-12-14 2019-05-21 Biontech Rna Pharmaceuticals Gmbh Yeni mhc bağımsız tümörle ilişkili antijenler.
JO3529B1 (ar) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
US9486475B2 (en) 2013-02-08 2016-11-08 Amgen Research (Munich) Gmbh PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
US10000546B2 (en) 2013-03-13 2018-06-19 Health Research, Inc. Compositions and method for use of recombinant T cell receptors for direct recognition of tumor antigen
CA2906970C (en) 2013-03-21 2021-05-18 Ospedale San Raffaele Srl Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
US9822162B2 (en) * 2013-07-15 2017-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human papillomavirus 16 E6 T cell receptors
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
WO2015091823A1 (en) * 2013-12-19 2015-06-25 Friedrich-Alexander Universität Erlangen-Nürnberg Influenza-specific t-cell receptor and its uses in the detection, prevention and/or treatment of influenza
US10654908B2 (en) 2014-04-15 2020-05-19 University Of Virginia Patent Foundation Isolated T cell receptors and methods of use therefor
KR102445667B1 (ko) * 2014-05-29 2022-09-21 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항-인유두종바이러스 16 e7 t 세포 수용체
EP3531133B1 (en) 2014-05-30 2023-08-23 Amgen Research (Munich) GmbH Risk-stratification of b-precursor acute lymphoblastic leukemia patients
EP3215168B1 (en) * 2014-10-31 2023-08-02 The Trustees of the University of Pennsylvania Altering gene expression in modified t cells and uses thereof
NZ736031A (en) 2015-04-06 2022-07-29 Regeneron Pharma Humanized t cell mediated immune responses in non-human animals
WO2016193299A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh T cell receptor library
EA201792661A1 (ru) * 2015-06-01 2018-05-31 Медиджин Иммьюнотерапиз Гмбх Способ получения антител против т-клеточного рецептора
KR101794304B1 (ko) * 2015-09-01 2017-11-06 가톨릭대학교 산학협력단 Ｅｂｖ 항원 특이 ｔ―세포 수용체 및 이의 용도
EP3347374A1 (en) * 2015-09-09 2018-07-18 Immune Design Corp. Ny-eso-1 specific tcrs and methods of use thereof
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
CN115925973A (zh) * 2015-10-23 2023-04-07 优瑞科生物技术公司 抗体/t细胞受体嵌合构建体及其用途
CN106632660B (zh) * 2015-11-04 2021-01-29 广东香雪精准医疗技术有限公司 识别ny-eso-1抗原短肽的tcr
JP6697562B2 (ja) 2015-12-23 2020-05-20 メディジーン イミュノテラピーズ ゲーエムベーハー 樹状細胞組成物
DK3402515T3 (da) 2016-01-12 2021-11-15 Oncotracker Inc Forbedrede fremgangsmåder til monitorering af et individs immunstatus
WO2017189254A1 (en) * 2016-04-26 2017-11-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-kk-lc-1 t cell receptors
US11827688B2 (en) 2016-06-02 2023-11-28 Immunocore Limited Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein
WO2018148454A1 (en) * 2017-02-09 2018-08-16 The Regents Of The University Of California Chimeric t cell antigen receptors and methods of use thereof
SG10201913655UA (en) 2017-04-26 2020-03-30 Eureka Therapeutics Inc Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
EP3622074A4 (en) 2017-05-12 2021-01-13 Augusta University Research Institute, Inc. HUMAN ALPHA FETOPROTEIN SPECIFIC T CELL RECEPTORS AND THEIR USES
US11635435B2 (en) 2017-06-13 2023-04-25 Oncotracker, Inc. Diagnostic, prognostic, and monitoring methods for solid tumor cancers
JP2020535128A (ja) 2017-09-19 2020-12-03 マサチューセッツ インスティテュート オブ テクノロジー キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
JP2020535832A (ja) * 2017-10-05 2020-12-10 アメリカ合衆国 マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法
AU2018346719A1 (en) * 2017-10-06 2020-04-23 Oslo Universitetssykehus Hf Chimeric antigen receptors
US20200316122A1 (en) 2017-10-11 2020-10-08 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of producing t cell populations using p38 mapk inhibitors
KR20190076297A (ko) 2017-12-22 2019-07-02 (주)메디톡스 Mart-1 특이적 t 세포 수용체 및 이의 용도
EP3749770A1 (en) 2018-02-09 2020-12-16 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Tethered interleukin-15 and interleukin-21
CN112262214A (zh) 2018-04-12 2021-01-22 优莫佳生物制药股份有限公司 病毒载体及包装细胞系
JP7469807B2 (ja) 2018-04-19 2024-04-17 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US20210275589A1 (en) * 2018-07-13 2021-09-09 Nanjing Legend Biotech Co. Ltd. Co-receptor systems for treating infectious diseases
CN110818802B (zh) * 2018-08-08 2022-02-08 华夏英泰（北京）生物技术有限公司 一种嵌合t细胞受体star及其应用
EP3884058A1 (en) 2018-11-21 2021-09-29 Umoja Biopharma, Inc. Multicistronic vector for surface engineering lentiviral particles
KR20200068263A (ko) 2018-12-05 2020-06-15 (주)메디톡스 Ny-eso-1 특이적 t 세포 수용체 및 이의 용도
CA3123511A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3946382A1 (en) * 2019-04-04 2022-02-09 UMC Utrecht Holding B.V. Modified immune receptor constructs
US11642409B2 (en) 2019-06-26 2023-05-09 Massachusetts Insttute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
WO2021183675A2 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Methods for generating engineered memory-like nk cells and compositions thereof
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US20210338833A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CA3191211A1 (en) 2020-09-08 2022-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell phenotypes associated with response to adoptive cell therapy
WO2022104035A2 (en) 2020-11-13 2022-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AU2022310862A1 (en) 2021-07-14 2024-02-01 Regeneron Pharmaceuticals, Inc. Engineered t cell receptors fused to binding domains from antibodies
WO2023002204A1 (en) * 2021-07-21 2023-01-26 Enara Bio Limited T-cell receptor
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023130040A2 (en) 2021-12-31 2023-07-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell therapy with vaccination as a combination immunotherapy against cancer
WO2023196996A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100246529B1 (ko) * 1990-12-14 2000-04-01 스티븐 에이. 서윈. 엠.디. 수용체 관련된 신호 변환 경로를 위한 키메라 사슬
US6407221B1 (en) * 1990-12-14 2002-06-18 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
EP1165578B1 (en) * 1999-03-19 2012-02-22 Waldemar Priebe Methods and compositions for the manufacture of c-3' and c-4' anthracycline antibiotics
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances

Also Published As

Publication number Publication date
CA2651174A1 (en) 2007-11-15
US20130116167A1 (en) 2013-05-09
DK2016102T3 (da) 2012-07-02
ATE550356T1 (de) 2012-04-15
WO2007131092A2 (en) 2007-11-15
EP2016102B1 (en) 2012-03-21
AU2007248019A1 (en) 2007-11-15
AU2007248019B2 (en) 2012-10-11
US20090304657A1 (en) 2009-12-10
ES2382777T3 (es) 2012-06-13
EP2016102A2 (en) 2009-01-21
WO2007131092A3 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
PT2016102E (pt) Recetores de célula t quimérica e materiais relacionados e métodos de uso
WO2004069876A3 (en) Trimeric polypeptide construct to induce an enduring t cell response
WO2008089053A3 (en) Gp100-specific t cell receptors and related materials and methods of use
MY177970A (en) Bcma (cd269/tnfrsf17) -binding proteins
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
CO6390070A2 (es) Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas incluyendo receptor de factor de crecimiento tipo insulina -i
Handl et al. Synthesis and evaluation of bivalent NDP-α-MSH (7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R)
MX362028B (es) Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
BRPI0806578A8 (pt) Promotores de lactococcus e usos dos mesmos
IN2012DN02981A (pt)
TW200607814A (en) Cell surface receptor isoforms and methods of identifying and using the same
PH12013502425B1 (en) Smoothened polypeptides and methods of use
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
MX2020009371A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión.
NZ585131A (en) Use melanocortins to treat insulin sensitivity
WO2005111204A3 (en) Porcine forssman synthetase cdna and polypeptide
Chaturvedi et al. The P-loop region of Schlafen 3 acts within the cytosol to induce differentiation of human Caco-2 intestinal epithelial cells
Maqboul et al. Expression profiles of TRPV1, TRPV4, TLR4 and ERK1/2 in the dorsal root ganglionic neurons of a cancer-induced neuropathy rat model
Zizak et al. Na+/H+ exchanger NHE3 has 11 membrane spanning domains and a cleaved signal peptide: topology analysis using in vitro transcription/translation
ATE471336T1 (de) Das biomolekültransduktionsmotiv mph-1-btm und dessen verwendung
WO2004045544A3 (en) Autocrine growth factor receptor antibodies and methods
WO2005047469A3 (en) PORCINE ISOGLOBOSIDE 3 SYNTHASE PROTEIN, cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION
Wagner et al. The Shb scaffold binds the Nck adaptor protein, p120 RasGAP, and Chimaerins and thereby facilitates heterotypic cell segregation by the receptor EphB2
DK1807518T3 (da) Rekombinant alfa-fetoprotein, fremgangsmåde og midler til fremstilling heraf, sammensætninger baseret derpå og anvendelse heraf
Guerrini et al. N-and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands